Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/09/20
Coherus BioSciences (CHRS) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 04/30/20
Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes OfferingGlobeNewsWire • 04/15/20
Coherus BioSciences Announces Proposed Convertible Senior Subordinated Notes OfferingGlobeNewsWire • 04/14/20
Coherus BioSciences Provides First Quarter 2020 Financial Update and Fiscal Year 2020 COVID-19 Impact InsightsGlobeNewsWire • 04/13/20
Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/28/20
Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 02/11/20
Coherus BioSciences Offers Compelling Long-Term Gain Opportunities With Low RiskSeeking Alpha • 02/04/20
Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United StatesGlobeNewsWire • 01/13/20